WO1987002038A1 - Analyses immunologiques et vaccins contre le syndrome immuno-deficitaire acquis - Google Patents

Analyses immunologiques et vaccins contre le syndrome immuno-deficitaire acquis

Info

Publication number
WO1987002038A1
WO1987002038A1 PCT/US1986/002002 US8602002W WO8702038A1 WO 1987002038 A1 WO1987002038 A1 WO 1987002038A1 US 8602002 W US8602002 W US 8602002W WO 8702038 A1 WO8702038 A1 WO 8702038A1
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant
virus
protein
lav
peptide
Prior art date
Application number
PCT/US1986/002002
Other languages
English (en)
Inventor
Shiu-Lok Hu
Anthony F. Purchio
Linda Madisen
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of WO1987002038A1 publication Critical patent/WO1987002038A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Virus recombinants contrôlant l'expression de peptides ou de protéines en rapport avec les épitopes du LAV/HTLV III, l'agent étiologique du syndrome de la lymphadénopathie et du syndrome immuno-déficitaire acquis. Ces virus peuvent être formulés en tant que vaccins viro ou sous la forme de vaccins multivalents protégeant contre l'infection par le LAV/HTLV III. Sont également décrits des peptides antigéniques et des protéines en rapport avec les épitopes du LAV/HTLV III. Ces composés peuvent être préparés en utilisant des techniques d'ADN recombinant ou par synthèse chimique et peuvent être utilisés comme immunogènes dans des sous-unités de vaccins ou comme antigènes dans des immunoanalyses diagnostiques.
PCT/US1986/002002 1985-09-25 1986-09-25 Analyses immunologiques et vaccins contre le syndrome immuno-deficitaire acquis WO1987002038A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US77990985A 1985-09-25 1985-09-25
US779,909 1985-09-25
US84298486A 1986-03-27 1986-03-27
US842,984 1986-03-27
US90521786A 1986-09-09 1986-09-09
US905,217 1986-09-09

Publications (1)

Publication Number Publication Date
WO1987002038A1 true WO1987002038A1 (fr) 1987-04-09

Family

ID=27419757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1986/002002 WO1987002038A1 (fr) 1985-09-25 1986-09-25 Analyses immunologiques et vaccins contre le syndrome immuno-deficitaire acquis

Country Status (22)

Country Link
CN (1) CN1020752C (fr)
AT (1) ATA256786A (fr)
CH (1) CH676247A5 (fr)
DE (1) DE3690508T1 (fr)
DK (1) DK455486A (fr)
ES (2) ES2002490A6 (fr)
FI (1) FI863848A (fr)
FR (1) FR2587720A2 (fr)
GB (1) GB2181435B (fr)
GR (1) GR862412B (fr)
HU (1) HU205780B (fr)
IE (1) IE59314B1 (fr)
IL (1) IL80073A (fr)
IT (1) IT1195829B (fr)
MY (1) MY103182A (fr)
NL (1) NL8602422A (fr)
NO (1) NO863803L (fr)
NZ (1) NZ217645A (fr)
PT (1) PT83434B (fr)
SE (4) SE8604007L (fr)
WO (1) WO1987002038A1 (fr)
YU (1) YU46753B (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0220234A1 (fr) * 1985-04-08 1987-05-06 Genetic Systems Corp EXPRESSION ET UTILISATION DIAGNOSTIQUE DE PEPTIDES CODES gag ET IMMUNOLOGIQUEMENT REACTIFS A DES ANTICORPS DU LAV.
DE3711016A1 (de) * 1986-04-04 1987-10-08 Hoffmann La Roche Expression und reinigung eines htlv-iii gag/env fusionsproteins
EP0260714A2 (fr) * 1986-09-19 1988-03-23 Oncogen Limited Partnership Utilisation de lymphocytes T actives dans la préparation d'un médicament pour le traitement du SIDA
WO1988005440A1 (fr) * 1987-01-16 1988-07-28 Institut Pasteur Peptides ayant des proprietes immunologiques 2-hiv-2
FR2610632A1 (fr) * 1987-02-11 1988-08-12 Pasteur Institut Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
WO1988010267A1 (fr) * 1987-06-24 1988-12-29 Proteus Biotechnology Limited Peptides synthetiques apparentes a des proteines hiv-env
EP0342860A2 (fr) * 1988-05-12 1989-11-23 Dana Farber Cancer Institute Nouvelle protéine, séquences contenant le gène de cette protéine, vecteurs, procédés de préparation et utilisation
WO1991000904A1 (fr) * 1988-06-03 1991-01-24 Smithkline Beckman Corporation EXPRESSION DE LA PROTEINE gag DE RETROVIRUS DANS DES CELLULES EUCARYOTIQUES
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5736368A (en) * 1988-06-10 1998-04-07 Therion Biologics Corporation Self assembled defective non-self propagating lentiviral particles
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US7803524B2 (en) 1994-02-23 2010-09-28 Siemens Healthcare Diagnostics Products Gmbh Antigenic HIV gp41 chimeric polypeptides comprising the MVP5180/91 epitope SKGKLIS
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US9421166B2 (en) 2001-12-19 2016-08-23 Novartis Ag Pulmonary delivery of aminoglycoside
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
IE872748L (en) * 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
JPS63258575A (ja) * 1986-12-15 1988-10-26 レプリゲン　コーポレーション 昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
DE10399032I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
FR2620030B1 (fr) * 1987-09-07 1990-03-23 Transgene Sa Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
DE68917520T2 (de) * 1988-05-06 1995-01-05 Ferropas Ag Verfahren und Systeme zur Herstellung von HIV-Antigenen.
AU3775789A (en) * 1988-06-10 1990-01-05 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
DE69031735T2 (de) * 1989-04-18 1998-03-12 Applied Biotechnology Inc Erzeugung von hybrid-genen und proteinen durch rekombination mittels viren
AU5848390A (en) * 1989-06-01 1991-01-07 Applied Biotechnology, Inc. Self-assembled, defective, non-self-propagating viral particles
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
FR2676068B1 (fr) * 1991-05-02 1994-11-04 Pasteur Institut Souches recombinantes immunogenes de b. anthracis - compositions immunogenes les contenant.
US5840312A (en) * 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
CA2120137C (fr) * 1991-11-08 2004-05-04 The Upjohn Company Vaccins contre le virus de la leucemie feline
CA2212682A1 (fr) 1995-02-10 1996-08-15 Worcester Foundation For Experimental Biology, Inc. Apport de composes exogenes
US6013506A (en) * 1995-06-05 2000-01-11 Wardley; Richard C. Feline leukemia virus vaccines
DE59507617D1 (de) * 1995-09-06 2000-02-17 Schablonentechnik Kufstein Ag Verfahren zum Herstellen einer Siebdruckschablone
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6723558B1 (en) 1996-01-23 2004-04-20 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127839B1 (fr) * 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Procédé pour la préparation d'un vecteur recombinant d'expression de baculovirus
US4662514A (en) * 1983-11-01 1987-05-05 Charleswater Products, Inc. Electrically conductive polymeric tubes for static sensitive electronic devices
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
IL76082A (en) * 1984-08-22 1991-07-18 Us Health Molecular clones of the genome of htlv-iii and a process for the preparation thereof
GB8501473D0 (en) * 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
ATE250083T1 (de) * 1984-10-18 2003-10-15 Pasteur Institut Lav-antigene und -peptide
CA1341423C (fr) * 1984-10-31 2003-03-04 Paul A. Luciw Proteines recombinantes de virus associes au syndrome d'adenopathie et/ou au syndrome d'immuno-deficience acquise
ATE138100T1 (de) * 1984-12-24 1996-06-15 Genentech Inc Fusionen von aids-verwandten polypeptiden
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
NZ215867A (en) * 1985-04-19 1989-10-27 Hoffmann La Roche Aids envelope protein, dna vectors and method of production
FR2586427B1 (fr) * 1985-08-20 1988-12-09 Pasteur Institut Sequences de nucleotides et de polypeptides issus du virus visna et leur application a des essais de diagnostic et a la production de compositions immunogenes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CELL, (Cambridge, Massachusetts), Volume 41, issued July 1985, CROWL et al., "HTLV-III env Gene Products Synthesized in E. Coli are Recognized by Antibodies Present in the Sera of Aids Patients", page 979. *
NATURE, (London, England), Volume 312, issued 08 November 1984, HAHN et al., "Molecular Cloning of the HTLV-III Virus Associated with AIDS", pages 166-167. *
NATURE, (London, England), Volume 313, issued 07 February 1985, MUESING et al., "Nucleic Acid Structure and Expression of Human AIDS/Lymphadenopathy Retrovirus". *
PROC. NATL. ACAD. SCI. U.S.A., Volume 77, issued March 1980, SNYDER et al., "Specificity of Human Antibodies to Oncovirus Glycoproteins: Recognition of Antigen by Natural Antibodies Directed Against Carbohydrate Structures", page 1622. *
SCIENCE, (Washington, DC, USA), Volume 224, issued 04 May 1984, SARNGADHARAN et al., "Antibodies Reactive with Human T-Lymphotropic Retroviruses (HTLV-III) in the Serum of Patients with AIDS", page 506. *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0220234A1 (fr) * 1985-04-08 1987-05-06 Genetic Systems Corp EXPRESSION ET UTILISATION DIAGNOSTIQUE DE PEPTIDES CODES gag ET IMMUNOLOGIQUEMENT REACTIFS A DES ANTICORPS DU LAV.
EP0220234A4 (fr) * 1985-04-08 1988-11-09 Genetic Systems Corp EXPRESSION ET UTILISATION DIAGNOSTIQUE DE PEPTIDES CODES gag ET IMMUNOLOGIQUEMENT REACTIFS A DES ANTICORPS DU LAV.
DE3711016A1 (de) * 1986-04-04 1987-10-08 Hoffmann La Roche Expression und reinigung eines htlv-iii gag/env fusionsproteins
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
EP0260714A2 (fr) * 1986-09-19 1988-03-23 Oncogen Limited Partnership Utilisation de lymphocytes T actives dans la préparation d'un médicament pour le traitement du SIDA
EP0260714A3 (en) * 1986-09-19 1988-08-24 Oncogen The use of activated t-lymphocytes for preparing a pharmaceutical composition for the treatment of aids
EP0283327A2 (fr) * 1987-01-16 1988-09-21 Institut Pasteur Peptides ayant des propriétés immunologiques de HIV-2
EP0283327A3 (fr) * 1987-01-16 1989-01-04 Institut Pasteur Peptides ayant des propriétés immunologiques de HIV-2
WO1988005440A1 (fr) * 1987-01-16 1988-07-28 Institut Pasteur Peptides ayant des proprietes immunologiques 2-hiv-2
FR2610632A1 (fr) * 1987-02-11 1988-08-12 Pasteur Institut Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
WO1988010267A1 (fr) * 1987-06-24 1988-12-29 Proteus Biotechnology Limited Peptides synthetiques apparentes a des proteines hiv-env
EP0298633A2 (fr) * 1987-06-24 1989-01-11 Proteus Molecular Design Limited Polypeptides synthétiques
EP0298633A3 (fr) * 1987-06-24 1989-04-26 Proteus Molecular Design Limited Polypeptides synthétiques
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
EP0342860A3 (fr) * 1988-05-12 1990-10-10 Dana Farber Cancer Institute Nouvelle protéine, séquences contenant le gène de cette protéine, vecteurs, procédés de préparation et utilisation
US5288640A (en) * 1988-05-12 1994-02-22 Dana Farber Cancer Institute Sequences containing the vpu gene and vectors therefore methods of preparation and use
EP0342860A2 (fr) * 1988-05-12 1989-11-23 Dana Farber Cancer Institute Nouvelle protéine, séquences contenant le gène de cette protéine, vecteurs, procédés de préparation et utilisation
WO1991000904A1 (fr) * 1988-06-03 1991-01-24 Smithkline Beckman Corporation EXPRESSION DE LA PROTEINE gag DE RETROVIRUS DANS DES CELLULES EUCARYOTIQUES
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
US5736368A (en) * 1988-06-10 1998-04-07 Therion Biologics Corporation Self assembled defective non-self propagating lentiviral particles
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US6051410A (en) * 1988-06-10 2000-04-18 Therion Biologics, Corp. Self-assembled, defective, nonself-propagating viral particles
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US7803524B2 (en) 1994-02-23 2010-09-28 Siemens Healthcare Diagnostics Products Gmbh Antigenic HIV gp41 chimeric polypeptides comprising the MVP5180/91 epitope SKGKLIS
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US9439862B2 (en) 2000-05-10 2016-09-13 Novartis Ag Phospholipid-based powders for drug delivery
US9421166B2 (en) 2001-12-19 2016-08-23 Novartis Ag Pulmonary delivery of aminoglycoside

Also Published As

Publication number Publication date
SE9102975D0 (sv) 1991-10-14
CN86106632A (zh) 1987-05-13
DE3690508T1 (fr) 1988-06-23
NZ217645A (en) 1991-11-26
HU205780B (en) 1992-06-29
IL80073A (en) 1995-01-24
GR862412B (en) 1987-01-23
ES2002490A6 (es) 1988-08-16
MY103182A (en) 1993-05-29
ATA256786A (de) 1995-05-15
SE9102974D0 (sv) 1991-10-14
PT83434B (pt) 1988-07-29
NL8602422A (nl) 1987-04-16
SE9102976L (sv) 1993-04-15
IE862525L (en) 1987-03-25
IE59314B1 (en) 1994-02-09
CN1020752C (zh) 1993-05-19
GB8622987D0 (en) 1986-10-29
SE9102974L (sv) 1993-04-15
FR2587720A2 (fr) 1987-03-27
DK455486A (da) 1987-03-26
FR2587720B2 (fr) 1995-02-10
PT83434A (en) 1986-10-01
IT1195829B (it) 1988-10-27
IT8667730A0 (it) 1986-09-24
NO863803D0 (no) 1986-09-24
GB2181435B (en) 1990-01-10
YU46753B (sh) 1994-05-10
FI863848A (fi) 1987-03-26
DK455486D0 (da) 1986-09-24
FI863848A0 (fi) 1986-09-24
CH676247A5 (fr) 1990-12-28
ES2006941A6 (es) 1989-05-16
NO863803L (no) 1987-03-26
HUT42133A (en) 1987-06-29
SE9102975L (sv) 1993-04-15
SE9102976D0 (sv) 1991-10-14
YU165486A (en) 1989-08-31
SE8604007L (sv) 1987-03-26
GB2181435A (en) 1987-04-23
IL80073A0 (en) 1986-12-31
SE8604007D0 (sv) 1986-09-23

Similar Documents

Publication Publication Date Title
WO1987002038A1 (fr) Analyses immunologiques et vaccins contre le syndrome immuno-deficitaire acquis
US5989562A (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
AU712431B2 (en) Recombinant attenuated ALVAC canarypox expression vectors containing heterologous DNA segments encoding lentiviral gene products
AU636944B2 (en) Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens
US7255862B1 (en) ALVAC/FIV constructs
US5614404A (en) Self-assembled, defective, non-self-propagating lentivirus particles
US5766598A (en) Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
Ahmad et al. Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus
WO1991019803A1 (fr) Particules virales autoassemblees defectueuses qui ne se propagent pas d'elles-memes
CZ266798A3 (cs) Syntetický polynukleotid obsahující DNA sekvence kódující HIV proteiny
US5747324A (en) Self-assembled, defective, non-self-propagating lentivirus particles
Winter et al. Recombinant BCG strains expressing the SIVmac251nef gene induce proliferative and CTL responses against nef synthetic peptides in mice
DK175613B1 (da) Virusvektor, der koder for et glycoprotein fra det virus, der er ansvarligt for AIDS, vaccine, der omfatter virusvektoren eller glycoproteinet, samt antistof mod glycoproteinet
RU2302461C2 (ru) Химерный ген cr3 и кодируемый им химерный белок cr3 (варианты), индуцирующий иммунный ответ против вич-1
FI114318B (fi) Menetelmä rekombinanttiadenovirusrokotteiden valmistamiseksi
ES2198400T3 (es) Vector que codifica particulas virales no autopropagantes, defectuosas, auto-ensambladas.
VAN EENDENBURG et al. Cell-mediated immune proliferative responses to HIV-1 of chimpanzees vaccinated with different vaccinia recombinant viruses
KR100347220B1 (ko) 재조합아데노바이러스hiv백신
Van der Ryst et al. Study of the immunogenicity of different recombinant Mengo viruses expressing HIV1 and SIV epitopes
AU608205B2 (en) Vaccines against acquired immune deficiency syndrome
JPS6368075A (ja) 後天性免疫不全症候群に関するワクチンおよび免疫検定法
IE904161A1 (en) Nonreplicating recombinant-made retroviral particles useful¹as anti-viral agents and as immunogens for prophylaxis and¹therapy against human retroviruses
US20030124146A1 (en) Recombinant Rhabdoviruses as live-viral vaccines
PH26855A (en) Vaccines against acquired immune deficiency syndrome
Sugata et al. Immune response of mice infected with recombinant vaccinia viruses carrying the HIV gag gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): DE

RET De translation (de og part 6b)

Ref document number: 3690508

Country of ref document: DE

Date of ref document: 19880623

WWE Wipo information: entry into national phase

Ref document number: 3690508

Country of ref document: DE